Pseudomonas aeruginosa is a gram-negative opportunistic pathogen that poses a major threat to immunocompromised individuals such as patients with cancer, burn wounds, or cystic fibrosis (1). The success of P. aeruginosa as a pathogen is due to its intrinsic and acquired antibiotic resistance mechanisms, infection in individuals with underlying diseases, ability to establish robust biofilms, and the production of numerous toxic products, all contribute to the difficulty in treating such life-threatening infections (2, 3). As mentioned, this bacterium has the ability to easily acquire antimicrobial resistance. The emergence of multiple drug-resistant strains has become a major clinical problem due to limited treatment options (4). Therefore, immunoprophylaxis and immunotherapy may be effective methods for controlling P. aeruginosa infections and due to this, development of a vaccine has become a necessity (5). A primary approach to developing a vaccine against this organism has involved searching for P. aeruginosa virulence factors that generate protective antibodies (6). An important virulence factor of P. aeruginosa is the LPS located in the outer portion of the outer membrane which promotes infection by interference with the host immune response (1, 7). LPS has been implicated as a critical virulence factor or protective antigen or both when examined in experimental animal models. Anti-LPS antibody has been shown to play a key role in protection against P. aeruginosa infections (8). Therefore, LPS is capable of acting as a target for effective immunity against P. aeruginosa infections (9). Recently, Au NPs have received attention due to their potential use over traditional vaccine platforms. The location of Au NPs in lymphoid tissues and cells, their capacity of coupling to a variety of biomolecules, their stability, ease of their synthesis, their unique physical properties (size and shape-dependent), and their safety (essential for the development and synthesis of vaccines) provide a multifaceted focus for the design of this new vaccine platform (10, 11). Furthermore, some in vitro and in vivo studies have revealed that various immune cells, including macrophages, dendritic cells, and lymphocytes, are stimulated by Au NPs leading to the production of proinflammatory cytokines (interleukin 1 β and tumor necrosis factor α) and T helper 1 cytokines (interferon γ and interleukin 2). Thus, the Au NPs can serve as both an antigen carrier and an adjuvant in immunization (12, 13). In this report, we describe the preparation and assessment of immunological properties of detoxified lipopolysaccharide-gold nanoparticles (D-LPS-Au NPs) conjugate, in order to determine whether conjugation onto Au NPs will enhance immunogenicity in mice.